Born Again isn't afraid top make some big changes to the sadistic supervillain Muse. Here's why that's a very good thing for ...

BDC-3042 is a proprietary agonist antibody that targets dectin-2, an immune-activating receptor expressed by tumor-associated macrophages (TAMs). This single-agent, dose-escalation Phase 1 clinical ...

Stifel lowered the firm’s price target on Bolt Biotherapeutics (BOLT) to $1.25 from $1.50 and keeps a Hold rating on the shares. Completion of ...